|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Earthworm fibrinolytic enzyme:anti-tumor activity on human hepatoma cells in vitro and in vivo显示文摘背景蚯蚓 fibrinolytic 酶(EFE ) 是在蚯蚓的消化的洞是广泛地分布式的复杂蛋白质酶。拥有的强壮的蛋白质水解作用活动, EFE 不仅血纤维蛋白上的直接效果,而且罐头激活 plasminogen。它的治疗学并且血栓相关的疾病上的预防效果临床上被证实了。最近,在那里被增加了对 EFE 的反肿瘤活动的兴趣。在这研究, EFE 的反肿瘤活动,从 Eisenia foetida 孤立,在人的 hepatoma 上,房间在 vitro 并且在包含的 vivo.The 潜力机制被评估也是在 vitro 实验的 studied.Methods 在四根人的 hepatoma 房间线被执行:有在各种各样的集中的 EFE 的 HLE, Huh7, PLC/PRF/5 和 HepG2.After 处理,房间增长的率的抑制被测量。为在里面 vivo 研究,有 Huh7 房间的忍受肿瘤的模特儿 xenografted 在裸体鼠标,然后鼠标被开发一天用 EFE 被喂一次 4 个星期,和接待的控制组仅仅盐。肿瘤生长上的禁止的效果被观察。另外, apoptosis 与流动 cytometric 试金被观察并且荧光灯与氮蒽橘子和 ethidium 溴化物(AO/EB ) 染色的染料。矩阵 metalloproteinase 的表示(MMP-2 ) 2 被西方的弄污的 assay.Results 与 EFE 的各种各样的集中在处理以后检测,所有 hepatoma 房间线的增长被压制到在 vitro 改变度。为 HLE, Huh7, PLC/PCF/5 和 HepG2 的 IC50 分别地是 2.11, 5.87, 25.29 和 17.30 uku/ml。在 EFE 的管理以后口头上地为 4 个星期,在裸体老鼠的 Huh7 房间的肿瘤异种皮移植的生长显著地在 vivo 被禁止。肿瘤在 EFE 500 uku/ 的禁止的率(kg 敨慰潴慭挠汥獬椠 ? 楶牴 ? 湡 ? 湩瘠? | CHEN Hong Shoichi Takahashi Michio Imamura Eiko Okutani ZHANG Zhi-guo Kazuaki Chayama CHEN Bao-an | 2007 | Chinese Medical Journal2007，，10： | 27 |
| 2 | Phase Ⅱ study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer显示文摘AIM: To test protracted irinotecan infusion plus a low-dose cisplatin in this Phase Ⅱ trial to decrease its toxic-ity. METHODS: The eligibility criteria were: (1) histologi-cally proven measurable gastric cancer; (2) performance status of 0 or 1; (3) no prior chemotherapy or comple-tion of prior therapy at least 4 wk before enrollment; (4) adequate function of major organs; (5) no other active malignancy; and (6) written informed consent. The regi-men consisted of irinotecan (60 mg/m2) on d 1 and 15 by 24-h infusion and cisplatin (10 mg/m2) on d 1, 2, 3, 15, 16, and 17. Treatment was repeated every 4 wk. RESULTS: Thirty-one patients were registered between April 2000 and January 2001. The response rate for all 31 patients, 20 patients without prior chemotherapy, and 11 patients with prior chemotherapy was 52% (16/31), 60% (12/20), and 36% (4/11), respectively. The median survival time was 378 d. The median number of courses given to all patients was 2. Grade 4 neutropenia oc-curred in 11 (35%) patients, while grade 3 to 4 diarrhea or nausea occurred in 1 (3%) and 3 (10%) patients, respectively. Fatigue was minimal as grade 1 fatigue was found only in 3 (10%) patients. Other adverse events were mild and no treatment-related deaths occurred.CONCLUSION: This regimen showed a high level of ac-tivity and acceptable toxicity in patients with metastatic gastric cancer. | Hiroshi Imamura Masataka Ikeda Hiroshi Furukawa Toshimasa Tsujinaka Kazumasa Fujitani Kenji Kobayashi Hiroyuki Narahara Michio Kato Haruhiko Imamoto Arimichi Takabayashi Hideaki Tsukuma | 2006 | World Journal of Gastroenterology2006，12，40： | 7 |
| 3 | Effects of a 24-week course of interferon-αtherapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma显示文摘AIM:To assess whether a 24-wk course of interferon (IFN)could prevent hepatocellular carcinoma(HCC) recurrence and worsening of liver function in patients with hepatitis C virus(HCV)-infected patients after receiving curative treatment for primary HCC. METHODS:Outcomes in 42 patients with HCV infection treated with IFN-α,after curative treatment for primary HCC(IFN group),were compared with 42 matched curatively treated historical controls not given IFN(non- IFN group). RESULTS:Although the rate of initial recurrence did not differ significantly between IFN group and non-IFN group (0%,44%,61%,and 67% vs 4.8%,53%,81%,and 87% at 1,3,5,and 7 years,P=0.153,respectively), IFN group showed a lower rate than the non-IFN group for second recurrence(0%,10.4%,28%,and 35% vs 0%,30%,59%,and 66% at 1,3,5 and 7 years, P=0.022,respectively).Among the IFN group,patients with sustained virologic response(SVR)were less likely to have a second HCC recurrence than IFN patients without an SVR,or non-IFN patients.Multivariate analysis identified the lack of SVR as the only independent risk factor for a second recurrence,while SVR and Child-Pugh class A independently favored overall survival. CONCLUSION:Most intrahepatic recurrences of HCV- related HCC occurred during persistent viral infection. Eradication of HCV is essential for the prevention of HCC recurrence and improvement of survival. | Soo Cheol Jeong Hiroshi Aikata Yoshio Katamura Takahiro Azakami Tomokazu Kawaoka Hiromi Saneto Kiminori Uka Nami Mori Shintaro Takaki Hideaki Kodama Koji Waki Michio Imamura Hiroo Shirakawa Yoshiiku Kawakami Shoichi Takahashi Kazuaki Chayama | 2007 | World Journal of Gastroenterology2007，13，40： | 3 |
| 4 | Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma显示文摘AIM: To assess the efficacy of low-dose intermittent interferon (IFN) therapy in patients with hepatitis C virus (HCV)-related compensated cirrhosis who had received curative treatment for primary hepatocellular carcinoma (HCC). METHODS: We performed a prospective case controlled study. Sixteen patients received 3 MIU of natural IFN- alpha intramuscularly 3 times weekly for at least 48 wk (IFN group). They were compared with 16 matched historical controls (non-IFN group). RESULTS: The cumulative rate of first recurrence of HCC was not significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 68.6% vs 80% at 1- and 3-year, P = 0.157, respectively). The cumulative rate of second recurrence was not also significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 35.9% vs 67% at 1- and 3-year, P = 0.056, respectively). Although the difference in the Child-Pugh classification score between the groups at initial treatment of HCC was not signifi cant, the score was signifi cantly worse at the time of data analysis in the non-IFN group than IFN group (7.19 ± 1.42 vs 5.81 ± 0.75, P = 0.0008). The cumulative rate of deviation from objects of any treatment for recurrentHCC was also higher in the non-IFN group than IFN group (6.7% and 27% vs 0 and 0% at 1- and 3-year, P = 0.048, respectively). CONCLUSION: Low-dose intermittent IFN-alpha therapy for patients with HCV-related compensated cirrhosis after curative HCC treatment was effective by making patients tolerant to medical or surgical treatment for recurrent HCC in the later period of observation. | Soocheol Jeong Hiroshi Aikata Yoshio Katamura Takahiro Azakami Tomokazu Kawaoka Hiromi Saneto Kiminori Uka Nami Mori Shintaro Takaki Hideaki Kodama Koji Waki Michio Imamura Hiroo Shirakawa Yoshiiku Kawakami Shoichi Takahashi Kazuaki Chayama | 2007 | World Journal of Gastroenterology2007，13，39： | 2 |
| 5 | IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients显示文摘 | Mayu Ohnishi Masataka Tsuge Tomohiko Kohno Yizhou Zhang Hiromi Abe Hideyuki Hyogo Yuki Kimura Daiki Miki Nobuhiko Hiraga Michio Imamura Shoichi Takahashi Hidenori Ochi C. Hayes Shinji Tanaka Koji Arihiro Kazuaki Chayama | 2012 | Journal of Gastroenterology2012，，7： | 1 |
| 6 | Circulating microRNA‐22 correlates with microRNA‐122 and represents viral replication and liver injury in patients with chronic hepatitis B显示文摘 | Keiko Arataki C. Nelson Hayes Sakura Akamatsu Rie Akiyama Hiromi Abe Masataka Tsuge Daiki Miki Hidenori Ochi Nobuhiko Hiraga Michio Imamura Shoichi Takahashi Hiroshi Aikata Tomokazu Kawaoka Hiroiku Kawakami Waka Ohishi Kazuaki Chayama | 2013 | J Med Virol2013，，5： | 1 |
| 7 | Interleukin‐28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation显示文摘 | Tomokazu Kawaoka Shoichi Takahashi Shintaro Takaki Akira Hiramatsu Koji Waki Nobuhiko Hiraga Daiki Miki Masataka Tsuge Michio Imamura Yoshiiku Kawakami Hiroshi Aikata Hidenori Ochi Takashi Onoe Hirotaka Tashiro Hideki Ohdan Kazuaki Chayama | 2012 | Journal of Gastroenterology and Hepatology2012，，9： | 1 |
| 8 | Circulating microRNA‐22 correlates with microRNA‐122 and represents viral replication and liver injury in patients with chronic hepatitis B显示文摘 | Keiko Arataki C. Nelson Hayes Sakura Akamatsu Rie Akiyama Hiromi Abe Masataka Tsuge Daiki Miki Hidenori Ochi Nobuhiko Hiraga Michio Imamura Shoichi Takahashi Hiroshi Aikata Tomokazu Kawaoka Hiroiku Kawakami Waka Ohishi Kazuaki Chayama | 2013 | J Med Virol2013，，5： | 1 |
| 9 | Long term persistence of NS5A inhibitor‐resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy显示文摘 | Satoshi Yoshimi Michio Imamura Eisuke Murakami Nobuhiko Hiraga Masataka Tsuge Yoshiiku Kawakami Hiroshi Aikata Hiromi Abe C. Nelson Hayes Tamito Sasaki Hidenori Ochi Kazuaki Chayama | 2015 | J. Med. Virol2015，，11： | 1 |
| 10 | Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats显示文摘 | Michio Imamura Tadashi Ogawa Yasuyuki Sasaguri Kazuaki Chayama Hikaru Ueno | 2005 | Gastroenterology2005，，1： | 1 |
| 11 | The long-term outcome of patients with bleeding gastric varices after balloon-occluded retrograde transvenous obliteration显示文摘 | Nobuhiko Hiraga Hiroshi Aikata Shintaro Takaki Hideaki Kodama Hiroo Shirakawa Michio Imamura Yoshiiku Kawakami Shoichi Takahashi Naoyuki Toyota Katsuhide Ito Shinji Tanaka Mikiya Kitamoto Kazuaki Chayama | 2007 | Journal of Gastroenterology2007，，8： | 1 |
| 12 | Recent trend of clinical features in patients with hepatocellular carcinoma显示文摘 | Yuko Nagaoki Hideyuki Hyogo Hiroshi Aikata Mio Tanaka Noriaki Naeshiro Takashi Nakahara Yoji Honda Daisuke Miyaki Tomokazu Kawaoka Shintaro Takaki Akira Hiramatsu Koji Waki Michio Imamura Yoshiiku Kawakami Shoichi Takahashi Kazuaki Chayama | 2012 | Hepatology Research2012，，4： | 1 |
| 13 | IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients显示文摘 | Mayu Ohnishi Masataka Tsuge Tomohiko Kohno Yizhou Zhang Hiromi Abe Hideyuki Hyogo Yuki Kimura Daiki Miki Nobuhiko Hiraga Michio Imamura Shoichi Takahashi Hidenori Ochi C. Hayes Shinji Tanaka Koji Arihiro Kazuaki Chayama | 2012 | Journal of Gastroenterology2012，，7： | 1 |
| 14 | Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma显示文摘 | Daiki Miki Hiroshi Aikata Kiminori Uka Hiromi Saneto Tomokazu Kawaoka Takahiro Azakami Shintaro Takaki Soo Cheol Jeong Michio Imamura Yoshiiku Kawakami Shoichi Takahashi Toshiyuki Itamoto Toshimasa Asahara Koji Arihiro Kazuaki Chayama | 2008 | Journal of Gastroenterology2008，，7： | 1 |
| 15 | Circulating microRNA‐22 correlates with microRNA‐122 and represents viral replication and liver injury in patients with chronic hepatitis B显示文摘 | Keiko Arataki C. Nelson Hayes Sakura Akamatsu Rie Akiyama Hiromi Abe Masataka Tsuge Daiki Miki Hidenori Ochi Nobuhiko Hiraga Michio Imamura Shoichi Takahashi Hiroshi Aikata Tomokazu Kawaoka Hiroiku Kawakami Waka Ohishi Kazuaki Chayama | 2013 | J. Med. Virol2013，，5： | 1 |
| 16 | Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b显示文摘 | Tomokazu Kawaoka C. Nelson Hayes Waka Ohishi Hidenori Ochi Toshiro Maekawa Hiromi Abe Masataka Tsuge Fukiko Mitsui Nobuhiko Hiraga Michio Imamura Shoichi Takahashi Michaki Kubo Tatsuhiko Tsunoda Yusuke Nakamura Hiromitsu Kumada Kazuaki Chayama | 2010 | Journal of Hepatology2010，，3： | 1 |
| 17 | Evaluation of shaping accuracy of sand mold based on stereo measurement显示文摘 | Tetsuo Miyake Michio Kaibeya takashi Imamura | 2009 | IEEE Computer Socity2009，，： | 1 |
| 18 | Amphipathic DNA Polymers Inhibit Hepatitis C Virus Infection by Blocking Viral Entry显示文摘 | Takuya Matsumura Zongyi Hu Takanobu Kato Marlene Dreux Yong–Yuan Zhang Michio Imamura Nobuhiko Hiraga Jean–Marc Juteau Francois–Loic Cosset Kazuaki Chayama Andrew Vaillant T. Jake Liang | 2009 | Gastroenterology2009，，2： | 1 |
| 19 | Management and clinical outcomes of type I gastric carcinoid patients: R etrospective, multicenter study in J apan显示文摘 | Yuichi Sato Hiroshi Imamura Yasuharu Kaizaki Wasaburo Koizumi Kenji Ishido Koichi Kurahara Haruhisa Suzuki Junko Fujisaki Katsuya Hirakawa Osamu Hosokawa Masanori Ito Michio Kaminishi Takahisa Furuta Tsutomu Chiba Ken Haruma | 2014 | Digestive Endoscopy2014，，3： | 1 |
| 20 | Periostin and bone marrow fibrosis显示文摘 | Eijiro Oku Taisuke Kanaji Yuka Takata Koichi Oshima Ritsuko Seki Satoshi Morishige Rie Imamura Korenori Ohtsubo Michitoshi Hashiguchi Koichi Osaki Kazuaki Yakushiji Kohji Yoshimoto Hideaki Ogata Hirofumi Hamada Kenji Izuhara Michio Sata Takashi Okamura | 2008 | International Journal of Hematology2008，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员